Heart Rhythm
Volume 3, Issue 10 , Pages 1196-1201, October 2006

Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter-defibrillator recipients

  • Jason Robin, MD

      Affiliations

    • Northwestern Memorial Hospital, Chicago, Illinois
  • ,
  • Kenneth Weinberg, MD

      Affiliations

    • Northwestern Memorial Hospital, Chicago, Illinois
  • ,
  • Jay Tiongson, MD

      Affiliations

    • Northwestern Memorial Hospital, Chicago, Illinois
  • ,
  • Mercedes Carnethon, PhD

      Affiliations

    • Northwestern University Feinberg School of Medicine, Chicago, Illinois
    • Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • ,
  • Madhavi Reddy, MD

      Affiliations

    • Northwestern Memorial Hospital, Chicago, Illinois
  • ,
  • Christina Ciaccio, MD

      Affiliations

    • Northwestern Memorial Hospital, Chicago, Illinois
  • ,
  • Michael Quadrini, MD

      Affiliations

    • Northwestern Memorial Hospital, Chicago, Illinois
  • ,
  • Jonathan Hsu, MD

      Affiliations

    • Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • ,
  • John Fan, MD

      Affiliations

    • Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • ,
  • Patrick Choi, BA

      Affiliations

    • Northwestern Memorial Hospital, Chicago, Illinois
  • ,
  • Alan Kadish, MD

      Affiliations

    • Northwestern University Feinberg School of Medicine, Chicago, Illinois
    • Department of Medicine, Cardiology Division, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • ,
  • Jeffrey Goldberger, MD

      Affiliations

    • Northwestern University Feinberg School of Medicine, Chicago, Illinois
    • Department of Medicine, Cardiology Division, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • ,
  • Rod Passman, MD, MSCE

      Affiliations

    • Northwestern University Feinberg School of Medicine, Chicago, Illinois
    • Department of Medicine, Cardiology Division, Northwestern University Feinberg School of Medicine, Chicago, Illinois
    • Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
    • Corresponding Author InformationAddress reprint requests and correspondence: Dr. Rod Passman, Cardiology Division, Northwestern Memorial Hospital, 201 East Huron, Suite 10-240, Chicago, Illinois 60611.

Received 6 March 2006; accepted 10 June 2006. published online 10 July 2006.

Background

Patients with end-stage renal disease are at increased risk for sudden cardiac death, although the utility of implantable cardioverter-defibrillators (ICDs) in these patients is unknown.

Objectives

The purpose of this study was to evaluate whether end-stage renal disease is an independent risk factor for appropriate ICD therapy for ventricular tachycardia (VT) or ventricular fibrillation (VF) and to compare the long-term survival of ICD recipients with and without end-stage renal disease.

Methods

A retrospective cohort study was performed on ICD recipients at a single center. The primary endpoint was first appropriate ICD therapy for VT/VF. The secondary endpoint was survival.

Results

The study included 585 patients, 19 (3.2%) of whom had end-stage renal disease prior to device implantation. Average follow-up time was 2.2 ± 2.4 years, during which time 156 patients (26.7%) received appropriate ICD therapy. End-stage renal disease was strongly associated with appropriate ICD therapy (hazard ratio 2.30, 95% confidence interval 1.17–4.54) and remained a significant predictor following adjustment for implant indication, ejection fraction, diabetes, hypertension, and beta-blocker use. Survival was significantly shorter in the end-stage renal disease patients, with a median survival time of 3.2 ± 0.6 (SEM) years in the dialysis cohort and 7.4 ± 0.5 (SEM) years in those without end-stage renal disease (log rank P = .009). The majority of deaths in the end-stage renal disease cohort were due to non–device-related infection.

Conclusion

In this cohort, end-stage renal disease was the single greatest predictor of ICD therapies for VT/VF. The survival rate was significantly shorter than that of ICD recipients without end-stage renal disease, suggesting that comorbidities in end-stage renal disease patients meeting current implant indications may reduce the survival benefit of ICD placement in this population.

Keywords:  Sudden cardiac death , Implantable cardioverter-defibrillator , Dialysis , End-stage renal disease

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr. Passman is funded by National Institutes of Health Grant K23 HL068814-01. This project is unsponsored. Drs. Kadish and Goldberger receive research funding from Medtronic, Guidant, and St. Jude. Dr. Passman receives research funding from Medtronic and St. Jude and receives salary support from a National Institutes of Health K23 award.

PII: S1547-5271(06)01709-7

doi:10.1016/j.hrthm.2006.06.013

Heart Rhythm
Volume 3, Issue 10 , Pages 1196-1201, October 2006